1-(5-(3,5-difluorophenyl)-3-(((1S,3R)-3-fluorocyclopentylamino)methyl)-4-methyl-1H-pyrazol-1-yl)propan-2-one | 1187306-92-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(5-(3,5-difluorophenyl)-3-(((1S,3R)-3-fluorocyclopentylamino)methyl)-4-methyl-1H-pyrazol-1-yl)propan-2-one
• 英文别名: 1-[5-(3,5-difluorophenyl)-3-[[[(1S,3R)-3-fluorocyclopentyl]amino]methyl]-4-methylpyrazol-1-yl]propan-2-one
• CAS: 1187306-92-8
• 化学式: C₁₉H₂₂F₃N₃O
• 分子量: 365.398
• InChiKey: ISINYRHGAOAMGJ-PBHICJAKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (1S,3R)-3-fluorocyclopentanamine 、 在 Zn(BH3CN)2 作用下， 以 甲醇 为溶剂， 生成 1-(5-(3,5-difluorophenyl)-3-(((1S,3R)-3-fluorocyclopentylamino)methyl)-4-methyl-1H-pyrazol-1-yl)propan-2-one
  参考文献：
  名称：

  Identification of MK-1925: A selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist

  摘要：

  Structure-activity relationship studies directed toward improving the metabolic stability of compound 1 resulted in the identification of 3-[5-(3,5-difluorophenyl)-3-({[(1S,3R)-3-fluorocyclopentyl]amino}methyl)-4-methyl-1H-pyrazol-1-yl]propanenitrile 39 (MK-1925) as a selective, orally available and brain-penetrable opioid receptor-like 1 (ORL1) antagonist. The compound also showed in vivo efficacy after oral dosing. Therefore, compound 39 was selected to undergo further studies as a clinical candidate. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.051

文献信息

• Identification of MK-1925: A selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist
  作者：Kensuke Kobayashi、Tomohiro Tsujita、Hirokatsu Ito、Satoshi Ozaki、Takeshi Tani、Yasuyuki Ishii、Shoki Okuda、Kiyoshi Tadano、Takahiro Fukuroda、Hisashi Ohta、Osamu Okamoto

  DOI：10.1016/j.bmcl.2009.06.051

  日期：2009.8

  Structure-activity relationship studies directed toward improving the metabolic stability of compound 1 resulted in the identification of 3-[5-(3,5-difluorophenyl)-3-([(1S,3R)-3-fluorocyclopentyl]amino}methyl)-4-methyl-1H-pyrazol-1-yl]propanenitrile 39 (MK-1925) as a selective, orally available and brain-penetrable opioid receptor-like 1 (ORL1) antagonist. The compound also showed in vivo efficacy after oral dosing. Therefore, compound 39 was selected to undergo further studies as a clinical candidate. (C) 2009 Elsevier Ltd. All rights reserved.